Revvity reported adjusted earnings per share of $1.70 for the fourth quarter, exceeding consensus estimates of $1.63 by 4.29%. This represents a year-over-year improvement from $1.42 in the same period last year and marks the fourth consecutive quarter the company has delivered an earnings surprise. In the previous quarter, Revvity beat estimates by 3.51%, underscoring its consistent operational execution across both its diagnostics and life sciences segments.

Fourth-quarter revenue reached $772.1 million, topping analyst forecasts of $763.1 million and reflecting 5.9% growth from $729.37 million a year earlier. This is the third time in four quarters that Revvity has outpaced consensus revenue projections. Strength in its core medical services business drove broad-based increases, with the diagnostics division benefiting from higher test volumes and the life sciences unit capitalizing on robust demand for research consumables.

Revvity’s financial position remains solid, with a debt-to-equity ratio of 0.46 indicating a moderate leverage profile and a current ratio of 1.75 suggesting ample liquidity to cover short-term obligations. Valuation metrics highlight investor confidence: the company’s price-to-earnings ratio stands at 50.83, price-to-sales ratio at 4.25 and enterprise-value-to-sales ratio at 5.11. An earnings yield of 1.97% and an enterprise-value-to-operating-cash-flow multiple of 25 further reflect the market’s premium on Revvity’s cash generation capabilities.

Management issued full-year 2026 guidance forecasting revenue growth in the mid-single digits and an EPS range above current consensus, driven by expected strength in the diagnostics business. Despite headwinds in academic research funding, the company anticipates margin expansion through operational efficiencies and continued uptake of its high-value molecular diagnostics portfolio. This outlook underscores Revvity’s confidence in sustaining both top-line growth and profitability enhancements over the next year.